Synonym
ARN22089; ARN 22089; ARN-22089
IUPAC/Chemical Name
N1,N1-dimethyl-N3-(6-phenyl-2-(piperidin-4-yl)pyrimidin-4-yl)benzene-1,3-diamine
InChi Key
BWJICNGLWINASO-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H27N5/c1-28(2)20-10-6-9-19(15-20)25-22-16-21(17-7-4-3-5-8-17)26-23(27-22)18-11-13-24-14-12-18/h3-10,15-16,18,24H,11-14H2,1-2H3,(H,25,26,27)
SMILES Code
CN(C)C1=CC=CC(NC2=NC(C3CCNCC3)=NC(C4=CC=CC=C4)=C2)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
373.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jahid S, Ortega JA, Vuong LM, Acquistapace IM, Hachey SJ, Flesher JL, La
Serra MA, Brindani N, La Sala G, Manigrasso J, Arencibia JM, Bertozzi SM, Summa
M, Bertorelli R, Armirotti A, Jin R, Liu Z, Chen CF, Edwards R, Hughes CCW, De
Vivo M, Ganesan AK. Structure-based design of CDC42 effector interaction
inhibitors for the treatment of cancer. Cell Rep. 2022 Apr 5;39(1):110641. doi:
10.1016/j.celrep.2022.110641. Erratum in: Cell Rep. 2022 Apr 26;39(4):110760.
PMID: 35385746; PMCID: PMC9127750.
2: Brindani N, Vuong LM, Acquistapace IM, La Serra MA, Ortega JA, Veronesi M,
Bertozzi SM, Summa M, Girotto S, Bertorelli R, Armirotti A, Ganesan AK, De Vivo
M. Design, Synthesis, In Vitro and In Vivo Characterization of
CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. J Med Chem.
2023 Apr 7. doi: 10.1021/acs.jmedchem.3c00276. Epub ahead of print. PMID:
37026468.
